Michael Hughes (@mshughes_md) 's Twitter Profile
Michael Hughes

@mshughes_md

Hematology-Oncology fellow at Columbia University, by way of Johns Hopkins Bayview and Harvard Medical School. Classics major. Thoughts/opinions my own.

ID: 1670910607749464071

calendar_today19-06-2023 21:45:29

55 Tweet

53 Takipçi

162 Takip Edilen

Raj Chakraborty (@rajshekharucms) 's Twitter Profile Photo

Diffuse lung involvement as a rare presentation of systemic AL amyloidosis (15 patients from a collective database of >2000 patients Università di Pavia & Herbert Irving Comprehensive Cancer Center)➡️Good organ response achievable after deep hematologic response, and lung transplant was feasible in one patient! Led by

Diffuse lung involvement as a rare presentation of systemic AL amyloidosis (15 patients from a collective database of &gt;2000 patients <a href="/unipv/">Università di Pavia</a> &amp; <a href="/columbiacancer/">Herbert Irving Comprehensive Cancer Center</a>)➡️Good organ response achievable after deep hematologic response, and lung transplant was feasible in one patient! Led by
Suzanne Lentzsch, MD, PhD (@slentzsch) 's Twitter Profile Photo

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint ir.prothena.com/investors/pres…

Michael Hughes (@mshughes_md) 's Twitter Profile Photo

Results from 4 pivotal phase 3 trials (MIDAS, PERSEUS, IsKIA, ADVANCE) representing current thinking on the role of ASCT in NDMM, masterfully summarized and contextualized by Suzanne Lentzsch, MD, PhD! #ASCO25 #MYELOMA #MRD Herbert Irving Comprehensive Cancer Center

Results from 4 pivotal phase 3 trials (MIDAS, PERSEUS, IsKIA, ADVANCE) representing current thinking on the role of ASCT in NDMM, masterfully summarized and contextualized by <a href="/SLentzsch/">Suzanne Lentzsch, MD, PhD</a>! #ASCO25 #MYELOMA #MRD <a href="/columbiacancer/">Herbert Irving Comprehensive Cancer Center</a>
Surbhi Sidana, MD (@surbhisidanamd) 's Twitter Profile Photo

#ASCO25 Looking forward to seeing CARTITUDE-1 long term presentation shortly! #mmsm 1 in 3 (32/97) patients alive and progression-free for ≥5 years - functional cure in my opinion. Simultaneous JCO pub, highlighted NY Times ascopubs.org/doi/10.1200/JC… nytimes.com/2025/06/03/hea…

#ASCO25 Looking forward to seeing CARTITUDE-1 long term presentation shortly! #mmsm 

1 in 3 (32/97) patients alive and progression-free for ≥5 years - functional cure in my opinion. 

Simultaneous JCO pub, highlighted NY Times

ascopubs.org/doi/10.1200/JC…

nytimes.com/2025/06/03/hea…
Raj Chakraborty (@rajshekharucms) 's Twitter Profile Photo

In another multicenter (Herbert Irving Comprehensive Cancer Center and Brigham and Women's Hospital) study of BCMA BsAb in AL Amyloidosis (including stage IIIb), brisk and deep hematologic responses translating into organ responses, despite short follow-up! Now we need: Prospective data Long term follow up to test

Michael Hughes (@mshughes_md) 's Twitter Profile Photo

Still have questions about that new 2025 IMS-IMWG definition of high risk #myeloma? Listen to a brief recap + Q&A on the paper at Journal of Clinical Oncology Article Insights I recorded with Nikhil C. Munshi, MD! ascopubs.org/do/jco-article… Herbert Irving Comprehensive Cancer Center Dana-Farber